Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

A Large Scale, Multicenter, Real-World Study on Patients With Advanced GIST Receiving Ripretinib

to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Ripretinib has become the standard ≥ 4L treatment in advanced GIST. Given the small sample size of patients in the China bridging study of INVICTUS as well as the short marketing time of ripretinib, further exploration on the long-term efficacy and safety of ripretinib, as well as the dominant gene mutation type of ripretinib in Chinese GIST patients is required. Hence, we plan to further explore the efficacy of ripretinib, predictors of efficacy, etc. by collecting and analyzing real-world data from Chinese patients with advanced GIST recieving ripretinib.

Inclusion Criteria:

-≥18 years old

• Histologically confirmed gastrointestinal stromal tumor (GIST)
• At least one measurable lesion (mRECIST v1.1)
• Received or receiving ripretinib treatment

Exclusion Criteria:

• Patients who received <1 cycle of ripretinib treatment
• Medical records are incomplete